• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胸膜间皮瘤组织学特征与基因改变的相关性

Correlation of Histologic Features with Gene Alterations in Pleural Mesothelioma.

作者信息

Fanaroff Rachel E, Yang Soo-Ryum, Tan Kay See, Adusumilli Prasad S, Bodd Francis, Bowman Anita, Chang Jason, Offin Michael D, Reiner Allison, Rekhtman Natasha, Rusch Valerie W, Travis William D, Zauderer Marjorie G, Ladanyi Marc, Sauter Jennifer L

机构信息

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland.

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

出版信息

Mod Pathol. 2025 May;38(5):100706. doi: 10.1016/j.modpat.2025.100706. Epub 2025 Jan 7.

DOI:10.1016/j.modpat.2025.100706
PMID:39788204
Abstract

Histologic features, including architectural patterns, cytologic features, and 2021 World Health Organization nuclear grade have been shown to have prognostic significance in epithelioid diffuse pleural mesothelioma (DPM). Biphasic and sarcomatoid DPM, regardless of morphology, have worse outcomes. These prognostic findings are well established but the correlation of architectural patterns, cytologic features, and nuclear grade with genetic alterations has not been well studied. To investigate relationships between histologic findings and genomic alterations, 128 treatment-naïve DPM specimens (70% epithelioid, 23% biphasic, and 6.3% sarcomatoid) with next-generation sequencing data were retrospectively reviewed. Alterations in BAP1 were the most common genomic alteration (n = 62, 48%), followed by CDKN2A (n = 49, 38%) and NF2 (n = 38, 30%). NF2 alterations were significantly more frequent in biphasic DPM (53% in biphasic vs 25% in sarcomatoid and 22% in epithelioid DPM; P = .005). In epithelioid DPM, TP53 alterations were associated with the presence of prognostically unfavorable histology, including micropapillary or solid architecture, pleomorphic features, and high nuclear grade. Tumors with low tumor-infiltrating lymphocytes (TILs) had a higher rate of BAP1 alterations than tumors with higher levels of TILs (67% vs 30%; P = .002). The findings of this study enhance our understanding of the relationships among prognostically significant histologic and molecular features of DPM and provide preliminary data to support increased integration of these findings in clinical diagnosis of pleural mesothelioma.

摘要

组织学特征,包括结构模式、细胞学特征和2021年世界卫生组织核分级,已被证明在上皮样弥漫性胸膜间皮瘤(DPM)中具有预后意义。双相型和肉瘤样DPM,无论形态如何,预后都较差。这些预后结果已得到充分证实,但结构模式、细胞学特征和核分级与基因改变之间的相关性尚未得到充分研究。为了研究组织学结果与基因组改变之间的关系,我们对128例未经治疗的DPM标本(70%为上皮样,23%为双相型,6.3%为肉瘤样)进行了回顾性分析,并获取了二代测序数据。BAP1改变是最常见的基因组改变(n = 62,48%),其次是CDKN2A(n = 49,38%)和NF2(n = 38,30%)。NF2改变在双相型DPM中明显更常见(双相型中为53%,肉瘤样中为25%,上皮样DPM中为22%;P = .005)。在上皮样DPM中,TP53改变与预后不良的组织学特征有关,包括微乳头或实性结构、多形性特征和高核分级。肿瘤浸润淋巴细胞(TILs)水平低的肿瘤比TILs水平高的肿瘤BAP1改变率更高(67%对30%;P = .002)。本研究结果增进了我们对DPM预后相关组织学和分子特征之间关系的理解,并提供了初步数据,以支持将这些结果更多地整合到胸膜间皮瘤的临床诊断中。

相似文献

1
Correlation of Histologic Features with Gene Alterations in Pleural Mesothelioma.胸膜间皮瘤组织学特征与基因改变的相关性
Mod Pathol. 2025 May;38(5):100706. doi: 10.1016/j.modpat.2025.100706. Epub 2025 Jan 7.
2
CDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma.CDKN2A基因缺失与弥漫性胸膜间皮瘤中的免疫沙漠化有关。
J Exp Clin Cancer Res. 2025 Aug 28;44(1):256. doi: 10.1186/s13046-025-03522-4.
3
Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.分析间皮瘤中改变的分布及其与形态学的相关性。
Am J Clin Pathol. 2023 Sep 1;160(3):238-246. doi: 10.1093/ajcp/aqad041.
4
Transcriptional landscape of pleural mesothelioma patients in relation to NF2 gene mutational status.与NF2基因突变状态相关的胸膜间皮瘤患者的转录图谱。
J Egypt Natl Canc Inst. 2025 Jun 9;37(1):25. doi: 10.1186/s43046-025-00284-0.
5
Inactivation of Cooperates with Losses of and to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models.Cooper 失活与 和 缺失协同作用驱动条件性小鼠模型中胸膜恶性间皮瘤的发展。
Cancer Res. 2019 Aug 15;79(16):4113-4123. doi: 10.1158/0008-5472.CAN-18-4093. Epub 2019 May 31.
6
Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials.肉瘤样恶性胸膜间皮瘤在临床试验中缓解率的系统评价
Lung Cancer. 2014 Nov;86(2):133-6. doi: 10.1016/j.lungcan.2014.08.017. Epub 2014 Sep 1.
7
The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.《2021年世界卫生组织胸膜肿瘤分类:自2015年分类以来的进展》
J Thorac Oncol. 2022 May;17(5):608-622. doi: 10.1016/j.jtho.2021.12.014. Epub 2022 Jan 10.
8
Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study.核分级和坏死可预测恶性上皮样胸膜间皮瘤的预后:一项多机构研究。
Mod Pathol. 2018 Apr;31(4):598-606. doi: 10.1038/modpathol.2017.170. Epub 2018 Jan 12.
9
The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.胸膜肉瘤样间皮瘤与肺梭形细胞/多形性(肉瘤样)癌的鉴别诊断:国际间皮瘤小组和MESOPATH国家参考中心的循证指南
Hum Pathol. 2017 Sep;67:160-168. doi: 10.1016/j.humpath.2017.07.015. Epub 2017 Aug 4.
10
BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma.BAP1、肾母细胞瘤蛋白1和钙视网膜蛋白在预测胸膜间皮瘤患者的生存率及一线化疗反应中的作用
J Cancer Res Clin Oncol. 2024 Jan 27;150(2):38. doi: 10.1007/s00432-023-05565-6.

引用本文的文献

1
DNA methylation-regulated HLA-C expression modulates immune responses and metabolic alterations to influence prognosis in mesothelioma.DNA甲基化调控的HLA-C表达调节免疫反应和代谢改变,以影响间皮瘤的预后。
Cancer Immunol Immunother. 2025 Mar 25;74(5):158. doi: 10.1007/s00262-025-04012-4.

本文引用的文献

1
BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma.BAP1缺陷会使肿瘤免疫微环境发生炎症反应,是恶性胸膜间皮瘤免疫治疗反应的候选生物标志物。
JTO Clin Res Rep. 2024 Mar 29;5(5):100672. doi: 10.1016/j.jtocrr.2024.100672. eCollection 2024 May.
2
Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma.比较免疫组织化学、下一代测序和荧光原位杂交在胸膜间皮瘤中检测 MTAP 缺失的应用。
Mod Pathol. 2024 Mar;37(3):100420. doi: 10.1016/j.modpat.2023.100420. Epub 2024 Jan 5.
3
Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
分析间皮瘤中改变的分布及其与形态学的相关性。
Am J Clin Pathol. 2023 Sep 1;160(3):238-246. doi: 10.1093/ajcp/aqad041.
4
Neurofibromatosis Type 2-Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif Dual Immunohistochemistry Is a Reliable Marker for the Detection of Neurofibromatosis Type 2 Alterations in Diffuse Pleural Mesothelioma.神经纤维瘤病 2 型相关蛋白和转录共激活因子与 PDZ 结合基序双重免疫组化是检测弥漫性胸膜间皮瘤中神经纤维瘤病 2 型改变的可靠标志物。
Mod Pathol. 2023 Mar;36(3):100030. doi: 10.1016/j.modpat.2022.100030. Epub 2023 Jan 10.
5
Genomic landscape of pleural and peritoneal mesothelioma tumours.胸膜和腹膜间皮瘤肿瘤的基因组图谱。
Br J Cancer. 2022 Nov;127(11):1997-2005. doi: 10.1038/s41416-022-01979-0. Epub 2022 Sep 22.
6
A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma.内在和外在特征的结合提高了恶性胸膜间皮瘤的预后预测。
Br J Cancer. 2022 Nov;127(9):1691-1700. doi: 10.1038/s41416-022-01950-z. Epub 2022 Aug 23.
7
BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study.免疫组织化学检测 BAP1 缺失可预测恶性胸膜间皮瘤患者一线铂类和培美曲塞化疗的生存获益:一项验证性研究。
J Thorac Oncol. 2022 Jul;17(7):921-930. doi: 10.1016/j.jtho.2022.04.008. Epub 2022 Apr 27.
8
Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.临床和分子验证 BAP1、MTAP、P53 和 Merlin 免疫组化在胸膜间皮瘤诊断中的应用。
Mod Pathol. 2022 Oct;35(10):1383-1397. doi: 10.1038/s41379-022-01081-z. Epub 2022 Apr 22.
9
The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.《2021年世界卫生组织胸膜肿瘤分类:自2015年分类以来的进展》
J Thorac Oncol. 2022 May;17(5):608-622. doi: 10.1016/j.jtho.2021.12.014. Epub 2022 Jan 10.
10
Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population.对澳大利亚真实世界人群中派姆单抗治疗恶性间皮瘤的回顾性评估。
JTO Clin Res Rep. 2020 Jul 16;1(4):100075. doi: 10.1016/j.jtocrr.2020.100075. eCollection 2020 Nov.